ORGANIZATION
PhRMA/EFPIA Deeply Concerned about MOF Pitch on Stringent CEA Application
US and European pharma lobbies on April 25 expressed their deep concerns over the Ministry of Finance’s (MOF) proposal calling for a stringent application of cost effective assessments (CEAs) in pricing and reimbursement decisions, urging the government to learn lessons…
To read the full story
Related Article
ORGANIZATION
- LLP Extra Patient Charge Influences Generic Adoption at Over 40% of Hospitals: FPMAJ
June 15, 2026
- FPMAJ Seeks Predictability in Price Maintenance System for Innovative Medicines
June 15, 2026
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
- Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
- Employees of 9 Pharma Firms Team Up for LGBTQ+ Inclusion
June 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





